Effect of cilostazol on lipid profile in hemodialysis patients

DOI Web Site 11 References
  • Otsubo Shigeru
    Department of Blood Purification, Sangenjaya Hospital Department of Nursing, Faculty of Human Care, Tohto College of Health Sciences
  • Yabuki Yasuko
    Department of Blood Purification, Sangenjaya Hospital
  • Ishihara Miwa
    Department of Blood Purification, Sangenjaya Hospital
  • Takasaki Masayo
    Department of Blood Purification, Sangenjaya Hospital
  • Ueda Syuitsu
    Department of Blood Purification, Sangenjaya Hospital
  • Sugimoto Hisayuki
    Department of Blood Purification, Sangenjaya Hospital
  • Otsubo Yuriko
    Department of Blood Purification, Sangenjaya Hospital
  • Nitta Kosaku
    Department of Medicine, Kidney Center, Tokyo Women's Medical University

Bibliographic Information

Other Title
  • 血液透析患者におけるシロスタゾールの血清脂質に与える影響
  • ケツエキ トウセキ カンジャ ニ オケル シロスタゾール ノ ケッセイ シシツ ニ アタエル エイキョウ

Search this article

Description

In Japan, cardiovascular disease was the most common cause of death in 2010. Cilostazol is recommended in the guidelines for the treatment of cerebral apoplexy and peripheral artery disease, and also reportedly increases the serum level of high-density lipoprotein (HDL) cholesterol and decreases that of triglycerides. However, the effects of cilostazol on lipid levels in hemodialysis patients have not previously been reported. We examined the effects of switching from aspirin to cilostazol on the lipid profiles of hemodialysis patients. Eight hemodialysis patients with peripheral arterial disease or a history of cerebral infarction who were being treated with aspirin were enrolled in this study. The patients’prescriptions were switched from aspirin (100mg/day) to cilostazol (100mg/day). We examined the serum levels of albumin, triglycerides, low-density lipoprotein (LDL) cholesterol, HDL cholesterol, apolipoprotein A1 (Apo A-1), apolipoprotein A2 (Apo A-2), and apolipoprotein B (Apo B) before and 1 month after the start of treatment with cilostazol. The serum levels of HDL cholesterol, Apo A-1, and Apo A-2 increased significantly (45.8±11.5 to 52.4±12.3mg/dL, p=0.003; 123.8±21.3 to 139.4±19.1mg/dL, p=0.004; and 26.4±4.3 to 28.9±3.6mg/dL, p=0.003; respectively). The serum level of triglycerides tended to decrease (103.0±70.0 to 83.1±39.5mg/dL, p=0.186). In hemodialysis patients, cilostazol might increase the serum level of HDL cholesterol, Apo A-1, and Apo A-2, similarly to its effects in non-hemodialysis patients.

Journal

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top